Eli Lilly’s Weight-Loss Drug Strategy Reveals How Pharmaceutical Power Actually Works
Eli Lilly announced Thursday that it will file for FDA approval of retatrutide, a next-generation weight-loss drug, in the first quarter of 2027. The drug performed well in late-stage trials, supporting weight loss and reducing some cardiovascular risk factors. By conventional measures of pharmaceutical success—efficacy, safety, clinical benefit—this should be straightforward news: a company developed…